These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 17109733

  • 21. A truncated-dose regimen of daclizumab for prevention of acute rejection in kidney transplant recipients: a single-center experience.
    Soltero L, Carbajal H, Sarkissian N, Khan AJ, Brennan S, Gonzalez JM, Truong LD, Suki WN.
    Transplantation; 2004 Nov 27; 78(10):1560-3. PubMed ID: 15599323
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M, Ming A, Zhao M.
    Clin Transplant; 2006 Nov 27; 20(3):325-9. PubMed ID: 16824149
    [Abstract] [Full Text] [Related]

  • 25. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
    Kuypers DR, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    Clin Transplant; 2003 Jun 27; 17(3):234-41. PubMed ID: 12780674
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.
    Rech AJ, Vonderheide RH.
    Ann N Y Acad Sci; 2009 Sep 27; 1174():99-106. PubMed ID: 19769742
    [Abstract] [Full Text] [Related]

  • 28. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
    Lietz K, John R, Beniaminovitz A, Burke EM, Suciu-Foca N, Mancini DM, Edwards NM, Itescu S.
    Transplantation; 2003 Mar 27; 75(6):781-7. PubMed ID: 12660501
    [Abstract] [Full Text] [Related]

  • 29. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients.
    Niemeyer G, Koch M, Light S, Kuse ER, Nashan B.
    Am J Transplant; 2002 May 27; 2(5):454-60. PubMed ID: 12123212
    [Abstract] [Full Text] [Related]

  • 30. A multicenter trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: interim analysis.
    Stratta RJ, Alloway RR, Lo A, Hodge E.
    Transplant Proc; 2001 May 27; 33(1-2):1692-3. PubMed ID: 11267472
    [No Abstract] [Full Text] [Related]

  • 31. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells.
    Xia G, He J, Zhang Z, Leventhal JR.
    Transplantation; 2006 Dec 27; 82(12):1749-55. PubMed ID: 17198271
    [Abstract] [Full Text] [Related]

  • 32. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J, Bono MR, Fierro A, Iñiguez R, Zehnder C, Rosemblatt M, Calabran L, Herzog C, Benavente D, Aguiló J, Pefaur J, Alba A, Ferrario M, Simon W, Contreras L, Buckel E.
    Transplant Proc; 2008 Nov 27; 40(9):3223-8. PubMed ID: 19010240
    [Abstract] [Full Text] [Related]

  • 33. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.
    van de Linde P, Vd Boog PJ, Tysma OM, Elliott JF, Roelen DL, Claas FH, de Fijter JW, Roep BO.
    Clin Exp Immunol; 2007 Jul 27; 149(1):56-62. PubMed ID: 17459076
    [Abstract] [Full Text] [Related]

  • 34. Impact of basiliximab on the proportion of regulatory T cells and their subsets early after renal transplantation: a preliminary report.
    Zhao T, Yang C, Xue Y, Qiu YY, Hu L, Qiu Y, Wang X, Yang B, Rong R, Xu M, Zhu T.
    Transplant Proc; 2012 Jan 27; 44(1):175-8. PubMed ID: 22310608
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
    Abramowicz D, Vanrenterghem Y, Squifflet JP, Kuypers D, Mourad M, Meurisse M, Wissing M.
    Clin Transplant; 2005 Aug 27; 19(4):475-82. PubMed ID: 16008591
    [Abstract] [Full Text] [Related]

  • 36. An investigation to assess the potential of CD25highCD4+ T cells to regulate responses to donor alloantigens in clinically stable renal transplant recipients.
    Akl A, Jones ND, Rogers N, Bakr MA, Mostafa A, El Shehawy el M, Ghoneim MA, Wood KJ.
    Transpl Int; 2008 Jan 27; 21(1):65-73. PubMed ID: 17887959
    [Abstract] [Full Text] [Related]

  • 37. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis.
    Ekberg H, Bäckman L, Tufveson G, Tydén G, Nashan B, Vincenti F.
    Transpl Int; 2000 Jan 27; 13(2):151-9. PubMed ID: 10836653
    [Abstract] [Full Text] [Related]

  • 38. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F, Phase III Daclizumab Study Group.
    Transplantation; 2001 Sep 15; 72(5):839-45. PubMed ID: 11571447
    [Abstract] [Full Text] [Related]

  • 39. Daclizumab induction in liver transplant recipients.
    Heffron TG, Smallwood GA, de Vera ME, Davis L, Martinez E, Stieber AC.
    Transplant Proc; 2001 Sep 15; 33(1-2):1527. PubMed ID: 11267408
    [No Abstract] [Full Text] [Related]

  • 40. Effect of regulatory T cells on short-term graft outcome in kidney transplant recipients, a prospective observational, single-center study.
    Bejugama K, Taduri G, Guditi S.
    Transpl Immunol; 2022 Aug 15; 73():101630. PubMed ID: 35643376
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.